


ZENECA
Pharmaceuticals
A Business Unit of Zeneca Inc.



1800 Concord Pike
Wilmington
Delaware 19850-5437 USA
Telephone (302) 886-2148
Fax (302) 886-5084

Robert W. Johnson
New Business Manager

March 17, 1998

Mr. Dennis Miller
Dr. Robert H. Harris
Federal Reserve Consultants
2139 Route 35
Holmdel, NJ 07733

Dear Dr. Harris and Mr. Miller:

While Dave McDonald is on a short medical leave, I am following up on several licensing projects he has been handling including Zeneca's review of Federal Research Consultants' compound ADD 234,037.

Our research group just recently completed their review of the data you provided on ADD 234,037. In summary, the team has raised various concerns related to safety, potency, dosing and breadth of efficacy. They have acknowledged that it is difficult to form a conclusive opinion based on this early animal data since some of your results do appear encouraging. However, they have stated that to achieve a greater comfort level in assessing this compound, they would want to see additional data after some limited multiple dosing in man is achieved. Therefore, if there is a chance to revisit this opportunity after this data is available, we would welcome hearing from you at that time.

Thank you for allowing Zeneca to evaluate our interest in ADD 234,037 at this stage. Again, we will be delighted to revisit this opportunity at a later date when additional data is available.

Sincerely,

Robert W. Johnson